Company

Red Queen Therapeutics, Inc.

Red Queen Therapeutics develops antiviral medicines using a stapled lipopeptide platform.

About

Red Queen Therapeutics develops antiviral treatments using a stapled lipopeptide platform designed to block virus-cell fusion. Its lead candidate, RQ-01, has been evaluated in Phase 1 trials. Based in Cambridge, US, the company raised USD 5.00 mn in Series A funding from Apple Tree Partners in October 2021.

1Funding rounds

1Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in